Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome
Status: Unknown
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• aged 18 years of age or older and presenting with cannabis hyperemesis syndrome requiring intravenous medication.
Locations
United States
Ohio
Mercy Health - Austintown
RECRUITING
Austintown
St Elizabeth Boardman Hospital
RECRUITING
Boardman
St. Joseph-Warren Hospital
RECRUITING
Warren
St Elizabeth Youngstown Hospital
RECRUITING
Youngstown
Contact Information
Primary
Todd Bolotin, MD
tbolotin@mercy.com
3302193838
Backup
Quincy Chopra, MD
qchopra@mercy.com
4128059742
Time Frame
Start Date: 2021-12-02
Completion Date: 2023-01-31
Participants
Target number of participants: 45
Treatments
Experimental: Intervention
Patients who receive droperidol 2.5mg intravenous once and diphenhydramine 25mg intravenous once
Related Therapeutic Areas
Sponsors
Collaborators: Lake Erie College of Osteopathic Medicine
Leads: Mercy Health Ohio